The levels of transforming growth factor-β1 are increased in the serum of patients with psoriasis and correlate with disease severity

European Journal of Dermatology

Volumn 6, Issue 7, 1996, Pages 486-490

  Bonifati, Claudio ^a   Carducci, Massimo ^a   Mussi, Anna ^a   Pittarello, Antonio ^a   D'Agosto, Giovanna ^a   Fazio, Marcello ^a   Ameglio, Franco ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

IL 1Ra; PASI; Psoriasis; sE selectin; Serum; sICAM 1; sL selectin; TGF 1

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; L SELECTIN; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PSORIASIS;

EID: 0029946627     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wahl SM, McCarteney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles or TGF-β. Immunology Today 1989; 10: 258-61.
2. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
3. Delaporte E, Nicolas JF, Thivolet J. Cytokines épidermiques et peau. Ann Dermatol Venereol 1989; 116: 511-7.
4. Massaguè J. Receptor for TGF-β family. Cell 1992; 69: 106-7.
5. Cerwenka A, Bevec D, Majdic O, Knapp W, Holter W. TGF-β1 is a potent inducer of human effector T-cells. J Immunol 1994; 153: 4367-76
6. Yamamoto H, Hirayama M, Genyea C, Kaplan J, TGF-β mediates natural suppressor activity of IL-2 activated lymphocytes. J Immunol 1994; 152: 3842-7.
7. Campos SP, Wang Y, Koj A, Baumann H. Divergent transforming growth factor-β effects on IL-6 regulation of acute phase plasma proteins in rat hepatoma cells. J Immunol 1993; 151: 7128-37.
8. Shipley GD, Pittelkow MR, Wille JJ, Scott RE, Moses HL. Reversible inhibition or normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986; 46: 2068-71.
9. Gruber BL, Marchese MJ, Kew RR. Transforming growth factor-β1 mediates mast cells chemotaxis. J Immunol 1994; 152: 5860-7.
10. Reichert W. I cheratinociti. In: Dubertret L, ed. Psoriasi. ISED, Brescia, 1993: 34-41.
11. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1, cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
12. Kane C, JM, Knapp AM, Mansbrige JN, Hanawalt PC. Transforming growth factor-β1 localization in normal and psoriatic epidermal keratinocytes in situ. J Cell 1990; 144: 144-50.
13. Schmid P, Cox D, McMaster GH, Itin P. In situ hybridization analysis of cytokine, proto-oncogene and tumor gene expression in psoriasis. Arch Dermatol Res 1993; 285: 334-40.
14. Fredrikson T, Patterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
15. Broekelman TJ, Limper AH, Colby TV, McDonald A. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6642-6.
16. Bonifati C, Solmone M, Trento E, Pietravalle M, Fazio M, Ameglio F. Serum interleukin-6 as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients. Int J Clin Lab Res 1994 24: 112-23.
17. Ameglio F, Bonifati C, Carducci M, Trento E, Mussi A, Tomaselli R, Onorati MT, Fazio M. Serum soluble E-selectin levels decrease early during effective therapy in psoriatic patients. Eur J Dermatol 1995; 5: 512-5.
18. Mussi A, Carducci M, Bonifati C, Pittarello A, Fazio M, Ameglio F. Are soluble membrane molecules reliable early markers for monitoring psoriasis? G Ital Dermatol Venereol 1995; 130: 73-5.
19. Katz AM, Rosenthal D, Sauder DN, Cell adhesion molecules. Structure, function, and implication in a variety of cutaneous and other pathologic conditions. Int J Dematol 1991: 30: 153-60.
20. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J Immunol 1993; 150: 4494-503.
21. Wahl SM, Costa GL, Corcoran M, Wahl LM, Berger AE. Transforming growth factor-β mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553-60.
22. Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitor. Eur Cytokine Nelw 1994; 5: 563-71.
23. Bonifati C, Ameglio F, Carducci M, Sacerdoti G, Pietravalle M, Fazio M. Interleukin-1-beta, interleukin-6 and interferon-gamma in suction blister fluids of involved and uninvolved skin and serum of psoriatic patients. Acta Derm Venereol (Stockh) 1994; 186: 23-4.
24. Cooper KD, Hammerberger C, Baadsgaard O, Elder JT, Chan LS, Sauder DN, Voorhees JJ, Fisher G. L-1 activity is reduced in psoriatic skin. Decreased IL-1a and increased nonfunctional IL-1β. J Immunol 1990; 144: 4593-603.
25. Shipley GD, Pittelkow MR, Wille JJ, Scott RE, Moses HL. Reversible inhibition of normal prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986; 46: 2068-71.
26. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126: 1-9.
27. Hancock GE, Kaplan G, Cohn ZA. Keratinocyte growth regulation by the products of immune cells. J Exp Med 1988; 168: 1395-8.
28. Bonifati C, Carducci M, Cordiali-Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F. Correlated increases of tumor necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and serum of psoriatic patients: relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-7.
29. Choy Y, Fuchs E. TGF-β and retinoic acid regulators of growth and modifiers of differentiation in human epidermal cells. Cell Regulation 1990; 1: 791-809.
30. Heng MCY, Allen SG, Chase DG. High endothelial venules in involved and uninvolved psoriatic skin: recognition by homing receptors on cytotoxic T-lymphocytes. Br J Dermatol 1988; 118: 315-26.
31. Ameglio F, Bonifati C, Carducci M, Alemanno L, Fazio M, Sacerdoti G, Fazio M. Soluble intercellular adhesion molecule-1 and procollagen III peptide represent reliable markers of disease severity in psoriasis. Acta Derm Venereol (Stockh) 1994; 186S: 19-20.